NO20064547L - Fremgangsmater for behandling av HIV infeksjon - Google Patents

Fremgangsmater for behandling av HIV infeksjon

Info

Publication number
NO20064547L
NO20064547L NO20064547A NO20064547A NO20064547L NO 20064547 L NO20064547 L NO 20064547L NO 20064547 A NO20064547 A NO 20064547A NO 20064547 A NO20064547 A NO 20064547A NO 20064547 L NO20064547 L NO 20064547L
Authority
NO
Norway
Prior art keywords
methods
hiv infection
treating hiv
treating
aids
Prior art date
Application number
NO20064547A
Other languages
English (en)
Other versions
NO337116B1 (no
Inventor
Pin-Fang Lin
Beata Nowicka-Sans
Gregory Yamanaka
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064547(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20064547L publication Critical patent/NO20064547L/no
Publication of NO337116B1 publication Critical patent/NO337116B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen omfatter farmasøytiske sammensetninger og fremgangsmåter for anvendelse av forbindelse I i kombinasjon med andre midler for behandling av pasienter med AIDS eller HIV-infeksjon.
NO20064547A 2004-03-24 2006-10-06 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioksoetyl]-piperazin eller et farmasøytisk akseptabelt salt derav, og minst et annet middel, anvendt for behandling av AIDS eller HIV-infeksjon samt farmasøytisk preparat omfattende samme NO337116B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (2)

Publication Number Publication Date
NO20064547L true NO20064547L (no) 2006-10-06
NO337116B1 NO337116B1 (no) 2016-01-25

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064547A NO337116B1 (no) 2004-03-24 2006-10-06 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioksoetyl]-piperazin eller et farmasøytisk akseptabelt salt derav, og minst et annet middel, anvendt for behandling av AIDS eller HIV-infeksjon samt farmasøytisk preparat omfattende samme

Country Status (30)

Country Link
US (1) US7776863B2 (no)
EP (1) EP1732604B1 (no)
JP (1) JP4847441B2 (no)
KR (1) KR101158140B1 (no)
CN (1) CN1956720B (no)
AR (1) AR048333A1 (no)
AT (1) ATE474602T1 (no)
AU (1) AU2005235116B2 (no)
BR (1) BRPI0509140A (no)
CA (1) CA2561146C (no)
CY (1) CY1111613T1 (no)
DE (1) DE602005022420D1 (no)
DK (1) DK1732604T3 (no)
ES (1) ES2347801T3 (no)
GE (1) GEP20104925B (no)
HR (1) HRP20100434T1 (no)
IL (1) IL178141A (no)
IN (1) IN2012DN06436A (no)
MY (1) MY144318A (no)
NO (1) NO337116B1 (no)
NZ (1) NZ549778A (no)
PE (1) PE20060148A1 (no)
PL (1) PL1732604T3 (no)
PT (1) PT1732604E (no)
RU (1) RU2367439C2 (no)
SI (1) SI1732604T1 (no)
TW (1) TWI347184B (no)
UA (1) UA88463C2 (no)
WO (1) WO2005102392A2 (no)
ZA (1) ZA200607959B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
EP2657235A1 (en) 2005-10-28 2013-10-30 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
JP5433691B2 (ja) * 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
WO2009158394A1 (en) * 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
US20110293686A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
WO2012019003A1 (en) 2010-08-06 2012-02-09 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
ES2585396T3 (es) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
DK2670751T3 (en) 2011-01-31 2015-07-20 Bristol Myers Squibb Co PROCEDURES FOR MANUFACTURING HIV BINDING INHIBITOR PRODUCT CONNECTION AND INTERMEDIATES
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
WO2013033061A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as hiv attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
EP2895472B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
WO2014025854A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Piperidine amide derivatives as hiv attachment inhibitors
US9586957B2 (en) * 2013-03-27 2017-03-07 VIIV Healthcare UK (No.5) Limited 2-keto amide derivatives as HIV attachment inhibitors
CN107847514A (zh) * 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762404B2 (en) * 1998-03-02 2003-06-26 Panacos Pharmaceuticals, Inc. Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
CA2469592C (en) * 2001-12-12 2005-08-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
PL369856A1 (en) * 2001-12-21 2005-05-02 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Also Published As

Publication number Publication date
EP1732604B1 (en) 2010-07-21
HK1096540A1 (en) 2007-06-01
RU2367439C2 (ru) 2009-09-20
AU2005235116B2 (en) 2011-03-31
JP2007530540A (ja) 2007-11-01
IL178141A0 (en) 2006-12-31
IN2012DN06436A (no) 2015-10-09
IL178141A (en) 2010-11-30
ATE474602T1 (de) 2010-08-15
US7776863B2 (en) 2010-08-17
CA2561146A1 (en) 2005-11-03
RU2006137555A (ru) 2008-04-27
TWI347184B (en) 2011-08-21
DK1732604T3 (da) 2010-11-15
KR20070011322A (ko) 2007-01-24
CA2561146C (en) 2013-12-24
GEP20104925B (en) 2010-03-25
WO2005102392A2 (en) 2005-11-03
NZ549778A (en) 2010-09-30
MY144318A (en) 2011-08-29
ZA200607959B (en) 2008-06-25
CN1956720A (zh) 2007-05-02
HRP20100434T1 (hr) 2010-09-30
SI1732604T1 (sl) 2010-10-29
PE20060148A1 (es) 2006-03-04
PT1732604E (pt) 2010-09-24
CN1956720B (zh) 2010-12-15
AU2005235116A1 (en) 2005-11-03
AR048333A1 (es) 2006-04-19
NO337116B1 (no) 2016-01-25
EP1732604A2 (en) 2006-12-20
KR101158140B1 (ko) 2012-06-19
US20050215545A1 (en) 2005-09-29
UA88463C2 (ru) 2009-10-26
TW200538117A (en) 2005-12-01
JP4847441B2 (ja) 2011-12-28
WO2005102392A3 (en) 2006-07-20
PL1732604T3 (pl) 2010-12-31
BRPI0509140A (pt) 2007-09-04
DE602005022420D1 (de) 2010-09-02
CY1111613T1 (el) 2015-10-07
ES2347801T3 (es) 2010-11-04

Similar Documents

Publication Publication Date Title
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
NO20070988L (no) Vaksine for forebygging og behandling av HIV-infeksjon
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
DK1458360T3 (da) Pulmonær afgivelse af aminoglycosider
MX2010002319A (es) Derivados indolicos 2,3 sustituidos para el tratamiento de infecciones virales.
DK2201840T3 (da) Hæmmere af Brutons tyrosinkinase
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
CY1109440T1 (el) Φωσφοϊνδολες ως αναστολεις hiv
NO20076405L (no) Anvendelse av 24-nor-UDCA
WO2006034001A3 (en) Methods of treating hiv infection
NO20071706L (no) Koadministrering av Tigecycline og Digoxin.
TW200738700A (en) HIV integrase inhibitors
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
UA110918C2 (uk) Інгібітори протеїнфосфатази-1 та їх застосування
RU2007145646A (ru) Средство для лечения вич-инфекции
WO2007081365A3 (en) Multiple antigenic agents and methods for using the same

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: VIIV HEALTHCARE UK (NO. 5) LIMITED, GB